Journal article
Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study
Abstract
OBJECTIVE: Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology.
RESEARCH DESIGN AND METHODS: We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, …
Authors
Bailey SD; Xie C; Do R; Montpetit A; Diaz R; Mohan V; Keavney B; Yusuf S; Gerstein HC; Engert JC
Journal
Diabetes Care, Vol. 33, No. 10, pp. 2250–2253
Publisher
American Diabetes Association
Publication Date
October 1, 2010
DOI
10.2337/dc10-0452
ISSN
0149-5992